Parecoxib for Pain Management After Total Knee Arthroplasty and Total Hip Arthroplasty

Perioperative Parecoxib Administration for Pain Management After Total Knee Arthroplasty and Total Hip Arthroplasty-A Randomized, Placebo-controlled Trial

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02272660

Enrollment

Registered

2014-10-23

Start date

2014-10-31

Completion date

2015-08-31

Last updated

2015-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative

Keywords

preemptive analgesia, parecoxib sodium, total knee arthroplasty, total hip arthroplasty

Brief summary

Evaluated the effect of perioperative parecoxib administration on postoperative pain, analgesic use, function recovery, inflammatory response and bleeding risk.

Detailed description

Non-steroid anti-inflammatory drugs are recommended for multimodal postoperative pain management. We evaluated the effect of perioperative parecoxib administration on postoperative pain, analgesic use, function recovery, inflammatory response and bleeding risk.

Interventions

DRUGParecoxib sodium

The patients in the parecoxib group received a single 40mg dose of parecoxib sodium 30 minutes before incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.

DRUGNormal saline injection

The patients in the control group received 2 mL normal saline injection 30 minutes before Normal saline injection incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

1. Male or female patients who have underwent primary unilateral total knee arthroplasty (TKA) and total hip arthroplasty (THA). 2. Age between 18-65 years. 3. Chinese ethnicity.

Exclusion criteria

1. patients who underwent a reversion or a previous TKA or THA, emergency TKA, or TKA as result of a trauma. 2. patient exhibited allergy to parecoxib sodium. 3. lactating or pregnant. 4. any other conditions not suitable for surgery as evaluated by the surgeon in charge.

Design outcomes

Primary

Measure	Time frame
To evaluate the Morphine consumption in each group patients	4 hours to 6 days after the surgery

Secondary

Measure	Time frame
To evaluate Patient-Controlled Intravenous Analgesia (PCIA) duration	4 hours to 6 days after the surgery
To evaluate the Visual Analog Scale (VAS) in each group patients underwent total knee arthroplasty and total hip arthroplasty	4 hours to 6 days after the surgery
Function recovery of knee Range of Motion (ROM) for patients received surgery	3 and 6 days after the surgery

Other

Measure	Time frame
Testing of body temperature,routine blood examination, IL-6 and IL-10	hospital admission and 1, 3, 6 days after the surgery

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026